{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:48Z","timestamp":1792598628722,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2019-12368506"],"award-info":[{"award-number":["GR-2019-12368506"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12376225"],"award-info":[{"award-number":["PNRR-MAD-2022-12376225"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013915","name":"Sarnoff Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymthe.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:45:39Z","timestamp":1768031139000},"page":"1340-1351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Niccol\u00f2","family":"Maurizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Ammirati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Argir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of Gene Therapy in Cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC. Heart Fail."},{"key":"10.1016\/j.ymthe.2026.01.004_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2021.01.016","article-title":"Considerations for Systemic Use of Gene Therapy","volume":"29","author":"Byrne","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131617","article-title":"Gene therapy vector-related myocarditis","volume":"398","author":"Silver","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.01.004_bib7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"11","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamaneurol.2024.4671","article-title":"An Imperative for Public Sharing of Adverse Events of Gene Therapy Trials","volume":"82","author":"Bonkowsky","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"15","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2026.01.004_bib11","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.01.004_bib12","unstructured":"https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251046546."},{"key":"10.1016\/j.ymthe.2026.01.004_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.01.004_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and Treatment of Acute Myocarditis: A Review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ymthe.2026.01.004_bib21","unstructured":"https:\/\/www.vigiaccess.org, accessed online on the 24th of April, 2025."},{"key":"10.1016\/j.ymthe.2026.01.004_bib22","unstructured":"https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard, accessed online on the 25th of April, 2025."},{"key":"10.1016\/j.ymthe.2026.01.004_bib23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib24","article-title":"Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1\/2 study (STAAR)","volume":"44","author":"Hughes","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.01.004_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2026.01.004_bib26","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib30","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.nmd.2022.07.234","article-title":"FP.28 IGNITE DMD phase I\/II study of SGT-001 microdystrophin gene therapy for DMD: Long-term outcomes and expression update","volume":"32","author":"Donisa","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.01.004_bib31","doi-asserted-by":"crossref","first-page":"104441-281","DOI":"10.1016\/j.nmd.2024.07.290","article-title":"410P GNT0004, Genethon\u2019s AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy, first data of the phase I\/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys","volume":"43","author":"Laugel","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.01.004_bib32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.01.004_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.22251","article-title":"Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D","volume":"68","author":"Mendell","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41591-023-02730-9","article-title":"Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E\/R4: phase 1\/2 trial results","volume":"30","author":"Mendell","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib38","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.01.004_bib41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib45","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib46","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.01.004_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.01.004_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.01.004_bib49","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ymthe.2026.01.004_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.01.004_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2026.01.004_bib52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/00185787231182562","article-title":"Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)-A Fondazione Policlinico Gemelli IRCCS Experience","volume":"59","author":"Favia","year":"2024","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ymthe.2026.01.004_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.01.004_bib56","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2026.01.004_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mus.27926","article-title":"Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children","volume":"68","author":"Chencheri","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2026.01.004_bib58","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_sref59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","article-title":"Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience","volume":"144","author":"Tokatly Latzer","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_sref60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy","volume":"118","author":"Matesanz","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","article-title":"Gene therapy for spinal muscular atrophy: the Qatari experience","volume":"28","author":"Ali","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.01.004_bib64","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib66","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jtha.2024.12.038","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","volume":"23","author":"Ozelo","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2026.01.004_bib67","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib68","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib69","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.01.004_bib70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hae.15121","article-title":"A phase 1\/2 safety and efficacy study of TAK-754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials","volume":"31","author":"Chapin","year":"2025","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2026.01.004_bib71","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib74","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib75","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib77","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib78","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib80","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(23)02874-X","article-title":"AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial","volume":"403","author":"Lv","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.01.004_bib81","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","article-title":"Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results","volume":"30","author":"Sevigny","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib82","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa2214084","article-title":"Gene Therapy in Patients with the Crigler-Najjar Syndrome","volume":"389","author":"D'Antiga","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib83","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200052","article-title":"Liver-Directed Adeno-Associated Virus-Mediated Gene Therapy for Mucopolysaccharidosis Type VI","volume":"1","author":"Brunetti-Pierri","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ymthe.2026.01.004_bib84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib85","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib86","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2021.135","article-title":"Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results","volume":"32","author":"Deiva","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib89","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib90","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ymthe.2026.01.004_bib91","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.01.004_bib92","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.01.004_bib93","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hc1102.105595","article-title":"Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris","volume":"105","author":"Grines","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.01.004_bib94","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","article-title":"A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina","volume":"42","author":"Grines","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.124.014054","article-title":"Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial","volume":"17","author":"Nakamura","year":"2024","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ymthe.2026.01.004_bib96","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D'Avola","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.01.004_bib97","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","article-title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment","volume":"13","author":"Stewart","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib98","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70014","article-title":"Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa)","volume":"48","author":"Weinstein","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.01.004_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.004_bib101","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ymthe.2026.01.004_bib102","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib103","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.004_bib104","unstructured":"https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study\/."},{"key":"10.1016\/j.ymthe.2026.01.004_bib105","unstructured":"https:\/\/4dmt.gcs-web.com\/news-releases\/news-release-details\/4dmt-presents-interim-data-4d-310-inglaxa-phase-12-clinical\/."},{"key":"10.1016\/j.ymthe.2026.01.004_bib106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on \u2018Safety and Challenges in Gene Transfer Therapy\u2019","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.01.004_bib107","unstructured":"https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp\/."},{"key":"10.1016\/j.ymthe.2026.01.004_bib108","unstructured":"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-provides-safety-update-elevidys-and-initiates-steps."},{"key":"10.1016\/j.ymthe.2026.01.004_bib109","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate Immune Sensing of Adeno-Associated Virus Vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:36:17Z","timestamp":1776371777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525001626000043"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.004","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}